Clovis Oncology, Inc. (CLVS) Social Stream



Clovis Oncology, Inc. (CLVS): $1.80

0.09 (+5.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLVS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Clovis Oncology Inc (CLVS) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Clovis Oncology Inc.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-04 4 $8 $4.75 $6.25 $2.5 150%
2022-02-23 3 $8 $3 $5.5 $2.5 120%
2022-03-31 3 $5 $3 $4 $2.5 60%

The Trend in the Analyst Price Target


CLVS's average price target has moved down $1.9 over the prior 34 weeks.

CLVS reports an average of 55.77% for its upside potential over the past 49 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-06-13 5 12 3.00 6.35 5.78 9.86%
2021-06-26 5 12 3.00 6.35 6.54 -2.91%
2021-08-14 5 10 3.00 5.90 4.78 23.43%
2021-11-04 3 8 6.00 7.00 4.57 53.17%
2021-11-04 4 8 4.75 6.25 4.57 36.76%

CLVS Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.67 1 0 1 0 0 3

The Trend in the Broker Recommendations


CLVS's average broker recommendation rating improved by 0.03 over the prior 23 months.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for CLVS as an investment opportunity.

  • To contextualize these metrics, consider that out of all US stocks, Clovis Oncology Inc's average analyst price target is greater than 14.63% of them.
  • In the context of stocks in the mid market cap category, Clovis Oncology Inc's number of analysts covering the stock is greater than 40.55% of them.
  • In terms of how Clovis Oncology Inc fares relative to stocks in the mid market cap category, note that its upside potential (average analyst target price relative to current price) is greater than 328.6% of that group.
  • Clovis Oncology Inc's variance in analysts' estimates is lower than -159.81% of stocks in the mid market cap category.

Stocks similar to Clovis Oncology Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are CERE, CCXI, and BPMC.

Is CLVS a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.515 seconds.